Company Products Research Collaborators Regulatory Investor Relations Contact Us  


Two new Canine Distemper Cases treated with PVX
May 10, 2014

In late April and early May Nuovo Biologics treated two additional dogs stricken with Canine Distemper using PVX, our experimental Anti-Viral. “Alfie” a mixed breed was treated with a low dose of PVX by David Schwartz at Boulevard Pet Clinic and recovered. “Sierra”, also a mixed-breed, was given PVX by Dr. Rick Palmquist at Centinela Animal Hospital. Both dogs recovered. Alfie is in the process of being adopted out by Lucky Puppy Rescue in Studio City, California, and Sierra has been returned to her Bay Area owners. Sierra’s condition was quite severe, including neurological signs such as facial ticks and involuntary limb movements. See video of Sierra today: (video)

Both Drs. Palmquist and Schwartz participated in earlier studies and are both strong advocates for the development of therapies for the treatment of Canine Distemper and other viral diseases which to day have eluded veterinarians.

Nuovo Biologics, LLC Reports Data on Canine Distemper Disease Pilot Study
May 15, 2013

In response to an outbreak of distemper in the Dallas Metroplex, and the surrounding areas, Nuovo Biologics has been working with Dr. Stephanie Polley to treat dogs with our investigational antiviral drug PVX. The distemper outbreak had led to the euthanasia of many animals and Nuovo's initial pilot project treated some forty-eight dogs so far. Forty two dogs have recovered, and several more are still undergoing treatment, and they are expected to survive. There was a significant reduction of disease symptoms, as well as reduction of viral loads as determined by PCR testing (a blood test designed to identify a virus and determine its level). Fourteen dogs were treated for distemper before Nuovo's drug was made available. The animals were treated with antibiotics and fluids for the most part. Less than 50% of those dogs survived. "I don't believe that many of these dogs would be alive today were it not for this new treatment", Dr. Polley states. All the dogs that recovered were either put up for adoption or returned to their owners. According to Dr. Jay Yourist, CEO of Nuovo Biologics, the results of the study support further testing.

FDA Center For Veterinary Medicine and Nuovo Biologics, LLC Schedule Meeting to Discuss Protocols
November 02, 2012

Nuovo Biologics, LLC has announced that on November 14, 2012 they will meet with the Office of New Animal Drug Evaluation (ONADE) Oncology team at the FDA Center of Veterinary Medicine in Rockville, MD. The purpose of this advisory meeting is to reach agreement on the key aspects of protocols for two clinical studies to support approval of a Conditional New Animal Drug Application (CNADA). The product is being evaluated as a potential treatment for canine oral stage II & III malignant melanoma. Nuovo's melanoma clinical research collaborators, Drs. Bruce Smith and R. Curt Bird, from Auburn University, College of Veterinary Medicine and Auburn University's Research Initiative in Cancer (AURIC) will be joining Nuovo Biologics CEO, Dr. Jay Yourist in this meeting.

While preparing for this meeting, Dr. Yourist stated, "We are on schedule and this will be a significant milestone in bringing our new drug to market. We expect that the discussion with FDA will pave the way for protocol concurrence and initiation of the planned clinical studies". Both the dose characterization and reasonable expectation of efficacy studywill be carried out at the College of Veterinary Medicine at Auburn University.

Nuovo Biologics, LLC is a Florida based biopharmaceutical company that is pursing innovative health products and technologies.

Robert G. Savage, Former Worldwide Chairman, Johnson & Johnson's Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
September 06, 2012

Nuovo Biologics, LLC announced that Robert G. Savage has joined its Board. Mr. Savage served as Group Vice President and President - General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003. From 1996 through 2001, Mr. Savage served Johnson & Johnson in a variety of roles, most recently as Worldwide Chairman of Johnson and Johnson's Pharmaceutical Group. From 1985 to 1996 he served Roche Holding AG in a variety of senior marketing, business development and operations positions, most recently as Vice President - Marketing, Hoffman-La Roche, Inc. He is currently a director of EpiCept Corporation and The Medicines Company. Mr. Savage was a member of the Board of Directors of Noven Pharmaceuticals, Inc. from 2004 until 2009 when the company was sold to Hisamitsu Pharmaceuticals Company. Mr. Savage has been the President of Strategic Imagery LLC, a pharmaceutical consultancy, since 2003.

Donald A. Denkhaus, Chairman of the Board of Nuovo Biologics, stated "We are exceptionally fortunate to have a pharmaceutical executive with such a wealth of experience join our Board. Bob's leadership, strategic vision and marketing experience will help move our company to the next level".

Dr. Jay Yourist, CEO, said "Nuovo's first drug in the U.S. will be a broad spectrum antiviral to treat companion animals. Ultimately, approval for human uses for our drugs will be sought. We are particularly pleased that Bob is joining our Board, especially in light of his past responsibility of developing and launching several antiviral and anti-bacterial drugs including Rocephin (ceftriaxone) and Tamiflu (oseltamivir) while he was at Roche and Levaquin (levofloxacin) while he was at Johnson & Johnson." Tamiflu is currently a leading antiviral drug with billions in sales globally since its launch.

Nuovo Biologics, LLC is a Florida based biopharmaceutical company that is pursing innovative health products and technologies.

Dr. Jay Yourist, Nuovo Biologics CEO To Speak At The World Animal Health Congress 2012
July 20, 2012

Dr. Jay Yourist, the President and CEO of Nuovo Biologics, LLC, a biopharmaceutical company headquartered in Davie, Florida has been invited to speak at this year's World Animal Health Congress.

This year's event, sponsored by Terrapinn, will be a two-day forum and parallel exhibition featuring senior-level speakers from pharma, biotech, diagnostics, and government and will be held in Kansas City, MO, November 27 - 28 2012.

Dr. Yourist will speak on building a new animal product research and development paradigm through partnerships and collaborations. This is the Nuovo Biologics development model and Dr. Yourist will address, amongst other things, the challenges in decentralizing drug development between multiple parties.

About Terrapinn
Terrapinn is a business media company. Its products are trade exhibitions, conferences, training solutions, electronic and print publications. Terrapinn owns a portfolio of business to business brands.

The company was established in Sydney, Australia in 1987 and now operates throughout the world from a network of offices in Sydney, Singapore, Johannesburg, New York, Dubai and London. The organization consists of approximately 400 staff and is led by an experienced management team headquartered in London.

About the World Animal Health Congress
The World Animal Health Congress is a senior-level business to business conference for animal drug companies seeking the best business strategies to maximize returns. It is a place where innovation is showcased, learning is done and new business contacts are made. By uniting senior-level animal health executives from big pharma together with CEOs and CSOs from leading small to mid-size pharma and biotechs, World Animal Health Congress USA provides an unrivalled platform to expose the most pressing business challenges of the industry. Discussing everything from regulatory compliance to delivering veterinary drugs to the market, it is the perfect opportunity to identify and approach new business prospects (


First - Previous - Next - Last Showing 6 to 10 of 37